GSK R&D Initiative Sees Early Success: Phase II NCEs Up Three-Fold
Executive Summary
GlaxoSmithKline's R&D productivity program has experienced some early successes in the number of compounds coming out of the early-stage pipeline
You may also be interested in...
GSK’s New Oncology R&D Structure Reflects Personalized Medicine Emphasis
GlaxoSmithKline's creation of a separate "GSK Oncology" R&D unit is not only intended to capture efficiency and strengthen its position in the crowded field - the firm is also aiming to further its personalized medicine research
GSK’s New Oncology R&D Structure Reflects Personalized Medicine Emphasis
GlaxoSmithKline's creation of a separate "GSK Oncology" R&D unit is not only intended to capture efficiency and strengthen its position in the crowded field - the firm is also aiming to further its personalized medicine research
Pipeline Dreams: GSK’s Witty Outlines Plans To Lower Phase III Attrition
As Andrew Witty takes the helm at GlaxoSmithKline, he has set his sights on tackling one of the industry's biggest challenges: reducing attrition in the late-stage pipeline